Arkstone's AI System Speeds Up Bacteremia Treatment

Arkstone Medical Solutions has published a study in Life (MDPI) showcasing the impact of its AI-driven clinical decision support system (CDSS) on the treatment of bacteremia, announced in a press release. Conducted in collaboration with Clinical Laboratory Roe in Lima, Peru, the study involved 117 patients and highlighted the system's ability to deliver accurate therapeutic recommendations 29 hours faster than traditional methods.

The research compared Arkstone's OneChoice Molecular Report (AOCHMR), which uses molecular data, with the OneChoice Fusion Report (AOCHFR), which combines molecular and phenotypic data. The findings showed an 80.3% concordance rate for primary therapeutic recommendations between the two reports and an 86.3% agreement in pathogen and resistance detection between molecular and culture testing.

The study emphasizes the potential of AI and machine learning technologies in clinical settings, particularly in regions with limited laboratory infrastructure. Arkstone's system aims to provide timely and precise guidance for severe infections like sepsis or bacteremia, addressing the challenges of antimicrobial resistance and improving patient outcomes.